Literature DB >> 20541447

Analysis of aberrantly spliced HRPT2 transcripts and the resulting proteins in HPT-JT syndrome.

Sungdae Moon1, Ju-Hee Kim, Ju-Yun Shim, Yu-Bae Ahn, Ki-Ho Song, Bong-Yun Cha, Lee-So Maeng, Je-Ho Han.   

Abstract

The risk for parathyroid carcinoma is high in those with the HPT-JT syndrome. Parafibromin is a protein derived from HRPT2 gene and its inactivation has been coupled to familial form of parathyroid malignancy. We previously identified altered transcripts resulting from splice site mutation of the HRPT2 gene in a family with this syndrome. In the present work, we investigated the stability of the altered HRPT2 transcripts and translation products produced in the HPT-JT syndrome. We quantified the differentially expressed HRPT2 mRNAs using real-time RT-PCR and developed a novel monoclonal parafibromin antibody to study the expression of parafibromin in the HPT-JT syndrome. The relative quantification ratios of the wild type HRPT2 mRNA, 23 bp deleted HRPT2 mRNA, and 70 bp deleted HRPT2 mRNA in the HPT-JT syndrome were 0.68, 0.17 and 0.15, respectively. But endogenous parafibromin expression was not detectable in the HPT-JT syndrome carcinoma. The altered HRPT2 mRNAs resulting from the splice site mutation in the HPT-JT syndrome were stable, but their parafibromin translation products from the HPT-JT syndrome carcinoma were probably degraded rapidly. Additional studies that aim to fully characterize the consequences of altered HRPT2 mRNAs in HPT-JT syndrome are required to explore these possibilities. Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541447     DOI: 10.1016/j.ymgme.2010.03.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  1 in total

1.  USP37 Deubiquitinates CDC73 in HPT-JT Syndrome.

Authors:  Su Yeon Kim; Ji-Young Lee; Yun-Jung Cho; Kwan Hoon Jo; Eun Sook Kim; Je Ho Han; Kwang-Hyun Baek; Sung-Dae Moon
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.